Ergoteles’s VYNE Therapeutics VYNE Stock Holding History

Ergoteles’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,822	Closed	-$557K	–	1714
2021 Q2	$557K	Buy	+8,822	New	+$698K	0.01%	757

Other funds holding VYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's VYNE Position: Q3 2021 in Review

Ergoteles sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 8,822 shares — an estimated $557K sold.

Ergoteles first reported a position in VYNE in Q2 2021 and held it in 1 quarter. The position peaked at $557K in Q2 2021. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

Ergoteles reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 8,822 VYNE Therapeutics shares in Q3 2021, an estimated $557K.
Ergoteles first reported a position in VYNE Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's VYNE Therapeutics position peaked at $557K in Q2 2021.
64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.